Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.
Vergez S, Delord JP, Thomas F, Rochaix P, Caselles O, Filleron T, Brillouet S, Canal P, Courbon F, Allal BC. Vergez S, et al. Among authors: filleron t. Clin Cancer Res. 2010 Sep 1;16(17):4434-45. doi: 10.1158/1078-0432.CCR-09-2795. Epub 2010 Jul 26. Clin Cancer Res. 2010. PMID: 20660574
Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors.
Zindy P, Bergé Y, Allal B, Filleron T, Pierredon S, Cammas A, Beck S, Mhamdi L, Fan L, Favre G, Delord JP, Roché H, Dalenc F, Lacroix-Triki M, Vagner S. Zindy P, et al. Among authors: filleron t. Cancer Res. 2011 Jun 15;71(12):4068-73. doi: 10.1158/0008-5472.CAN-11-0420. Epub 2011 Apr 15. Cancer Res. 2011. PMID: 21498638
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
Bellera CA, Pulido M, Gourgou S, Collette L, Doussau A, Kramar A, Dabakuyo TS, Ouali M, Auperin A, Filleron T, Fortpied C, Le Tourneau C, Paoletti X, Mauer M, Mathoulin-Pélissier S, Bonnetain F. Bellera CA, et al. Among authors: filleron t. Eur J Cancer. 2013 Mar;49(4):769-81. doi: 10.1016/j.ejca.2012.09.035. Epub 2012 Nov 2. Eur J Cancer. 2013. PMID: 23122780
αvβ3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma.
Ducassou A, Uro-Coste E, Verrelle P, Filleron T, Benouaich-Amiel A, Lubrano V, Sol JC, Delisle MB, Favre G, Ken S, Laprie A, De Porre P, Toulas C, Poublanc M, Cohen-Jonathan Moyal E. Ducassou A, et al. Among authors: filleron t. Eur J Cancer. 2013 Jun;49(9):2161-9. doi: 10.1016/j.ejca.2013.02.033. Epub 2013 Apr 6. Eur J Cancer. 2013. PMID: 23566417 Clinical Trial.
Prognostic relevance of celiac lymph node involvement in ovarian cancer.
Martínez A, Pomel C, Filleron T, De Cuypere M, Mery E, Querleu D, Gladieff L, Poilblanc M, Ferron G. Martínez A, et al. Among authors: filleron t. Int J Gynecol Cancer. 2014 Jan;24(1):48-53. doi: 10.1097/IGC.0000000000000041. Int J Gynecol Cancer. 2014. PMID: 24356411
229 results